2018 年第一季度报告 公司代码：603716 公司简称：塞力斯 武汉塞力斯医疗科技股份有限公司 2018 年第一季度报告 1 / 18 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 2018 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | | | | | 减(%) | | | 总资产 | 1,656,941,488.99 | 1,569,390,653.60 | | 5.58 | | 归属于上市公司 | 946,998,840.29 | 933,386,166.87 | | 1.46 | | 股东的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的 | -62,453,577.98 | -14,395,168.68 | | -333.85 ...

2017 年年度报告 公司代码：603716 公司简称：塞力斯 武汉塞力斯医疗科技股份有限公司 2017 年年度报告 1 / 223 2017 年年度报告 重要提示 三、 中审众环会计师事务所（特殊普通合伙）本公司出具了标准无保留意见的审计报告。 四、 公司负责人温伟、主管会计工作负责人刘文豪及会计机构负责人（会计主管人员）陈静声明： 保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 根据 2018 年 2 月 6 日公司第二届董事会第二十三次会议审议通过的《关于控股 股东提议 2017 年度利润分配及资本公积转增股本预案的议案》，公司拟以 2017 年度 利润分配方案实施时股权登记日的总股本为基数，向全体股东以每 10 股派发现金红 利人民币 1 元（含税），同时以资本公积转增股本，每 10 股转增 15 股。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质 承诺，请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供 ...

Financial Performance - Operating revenue for the first nine months reached CNY 617,434,962.28, a growth of 34.81% year-on-year[6] - Net profit attributable to shareholders increased by 11.17% to CNY 55,380,574.49 for the first nine months[6] - Operating revenue for Q3 2017 was CNY 257,166,243.17, compared to CNY 164,037,734.48 in Q3 2016, reflecting a year-over-year increase of approximately 57%[25] - Total revenue for Q3 2017 reached CNY 180,354,149.72, an increase from CNY 138,216,997.17 in Q3 2016, representing a growth of approximately 30.5%[28] - Net profit attributable to the parent company was CNY 18,252,025.96 in Q3 2017, compared to CNY 13,670,323.06 in Q3 2016, reflecting a year-over-year increase of about 33.5%[27] - The company reported a net profit of CNY 9,291,631.11 for Q3 2017, a decrease from CNY 20,056,867.14 in Q3 2016, showing a decline of about 53.7%[29] - Operating profit for the first nine months of 2017 was CNY 42,897,806.87, down from CNY 51,747,824.48 in the same period of 2016, indicating a decline of approximately 17.1%[28] Assets and Liabilities - Total assets increased by 32.97% to CNY 1,452,628,608.70 compared to the end of the previous year[6] - Total liabilities rose to CNY 494,667,031.07 from CNY 233,192,770.13, marking an increase of about 112%[21] - Total equity reached CNY 957,961,577.63, up from CNY 859,288,150.24, indicating a growth of around 11.5%[21] - Accounts receivable increased by 49.35% to ¥537.31 million from ¥359.77 million, driven by business expansion and subsidiary mergers[12] - Inventory rose by 116.14% to ¥164.38 million from ¥76.05 million, influenced by business expansion and subsidiary mergers[12] - The company’s goodwill reached ¥111.09 million, marking a 100% increase due to external investments[12] - The company’s total liabilities increased significantly, with accounts payable rising by 256.92% to ¥30.19 million from ¥8.46 million, influenced by settlement terms and subsidiary mergers[12] Cash Flow - The net cash flow from operating activities decreased by 28.44% to CNY -48,914,069.43 compared to the same period last year[6] - Cash and cash equivalents decreased by 42.96% to ¥201.81 million from ¥353.78 million due to the use of raised funds[12] - The company reported a net cash outflow from investing activities of ¥208.49 million, a 354.54% increase in outflow compared to the previous period[13] - Cash inflow from sales of goods and services reached ¥580.35 million, up from ¥440.91 million year-on-year, representing a 31.6% increase[30] - Net cash flow from operating activities was -¥48.91 million, compared to -¥38.08 million in the same period last year, indicating a decline in operational efficiency[30] - Total cash outflow from investing activities was ¥208.51 million, significantly higher than ¥45.87 million in the previous year, reflecting increased investment activities[31] - Cash inflow from financing activities amounted to ¥243.18 million, up from ¥123.02 million year-on-year, showing a 97.6% increase in financing efforts[31] - The ending cash and cash equivalents balance was ¥196.25 million, a decrease from ¥348.62 million at the beginning of the period, reflecting cash management challenges[31] Shareholder Information - The total number of shareholders reached 8,148 by the end of the reporting period[9] - The largest shareholder, Tianjin Ruimeike Instrument Co., Ltd., holds 46.1% of the shares[9] Government Subsidies and Non-Recurring Items - Government subsidies recognized in the current period amounted to CNY 571,400.00, with a total of CNY 5,361,400.00 for the year-to-date[8] - The company reported a total of CNY 792,174.13 in non-recurring gains and losses for the current period[8] Cost and Expense Management - Operating costs grew by 38.08% to ¥414.60 million from ¥300.26 million, reflecting the impact of business expansion and subsidiary mergers[13] - Sales expenses for the first nine months of 2017 amounted to CNY 28,174,403.19, up from CNY 25,153,509.09 in the same period of 2016, reflecting an increase of about 12%[28] - Cash outflow for purchasing goods and services was ¥483.61 million, up from ¥362.83 million, indicating increased operational costs[30] - Cash paid to employees increased to ¥53.40 million from ¥33.47 million, reflecting a 59.5% rise in labor costs[30] - Cash outflow for other operating activities rose to ¥53.12 million from ¥29.33 million, indicating higher operational expenses[30]

Financial Performance - The company's operating revenue for the first half of 2017 was ¥360,268,719.11, representing a 22.55% increase compared to ¥293,971,781.82 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was ¥37,128,548.53, a 2.72% increase from ¥36,143,722.46 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 7.6%, amounting to ¥33,421,944.88 compared to ¥36,171,738.01 in the same period last year[18]. - Basic earnings per share decreased by 23.16% to CNY 0.73 compared to the same period last year[19]. - The weighted average return on equity fell by 3.24 percentage points to 4.31% year-on-year[19]. - Operating profit decreased to ¥46,112,766.61, down 9.5% from ¥51,037,707.81 in the previous period[99]. - Total profit for the current period was ¥51,057,618.62, slightly up from ¥51,000,142.56 in the previous period[99]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥42,322,556.50, a significant decline from -¥8,794,663.84 in the previous year, representing a decrease of 381.23%[18]. - Cash flow from operating activities showed a net outflow of ¥42,322,556.50, worsening from a net outflow of ¥8,794,663.84 in the previous period[104]. - Cash and cash equivalents decreased to CNY 215,098,442.29 from CNY 353,784,266.90, a decline of about 39.2%[95]. - The total assets at the end of the reporting period were ¥1,277,840,518.13, which is a 16.97% increase from ¥1,092,480,920.37 at the end of the previous year[18]. - The company's total liabilities increased to CNY 360,650,141.90 from CNY 233,192,770.13, reflecting a rise of about 54.6%[95]. - The total equity attributable to shareholders reached CNY 876,667,330.40, up from CNY 843,613,981.87, indicating a growth of approximately 3.9%[96]. Investments and Capital Structure - The company plans to increase its total share capital by 2,037.6 million shares through a capital reserve transfer, raising the total share capital to 7,131.6 million shares[2]. - A proposed 1 billion yuan medical industry investment fund aims to strengthen the company's market positioning and growth potential[34]. - The company has successfully utilized 93.67% of the 314 million yuan raised from its IPO for various projects, including marketing and logistics improvements[36]. - A planned private placement aims to raise up to 1.052 billion yuan, with significant commitments from management and employees, indicating confidence in future growth[37]. - The company reported a total cash inflow from operating activities of CNY 288,346,724.36, an increase of 15.1% compared to CNY 250,573,285.32 in the previous period[107]. Operational Efficiency and Strategy - The company has established strategic partnerships with major suppliers, enhancing its procurement cost advantages[29]. - The company is focusing on expanding its customer base and deepening existing client relationships to maintain market leadership in the IVD sector[28]. - The company’s supply chain information management system has improved operational efficiency by handling over 6,000 products[29]. - The company aims to optimize regional diagnostic resource allocation through its innovative marketing and service model[27]. - The company initiated 94 new R&D projects, with 12 launched during the reporting period, enhancing its product line in various diagnostic areas[38]. Governance and Compliance - The company has received a standard unqualified audit report from Zhongshun Zhonghuan Accounting Firm[4]. - The company has strengthened its governance structure, holding multiple board meetings and enhancing internal control systems[39]. - Investor relations management has been improved to foster better communication and protect shareholder interests[40]. - The company has established measures to ensure that no unfair benefits are transferred to other entities or individuals, protecting shareholder interests[53]. - The company will implement a stock incentive plan linked to the execution of its compensation measures, ensuring alignment with shareholder interests[53]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, urging investors to be cautious[4]. - The company has no major litigation or arbitration matters during the reporting period[59]. - The company has not reported any major related party transactions during the reporting period[63]. Shareholder Information - The top ten shareholders held a total of 46.10% of shares, with Tianjin Ruimei Scientific Instrument Co., Ltd. being the largest shareholder[77]. - The company reported a total of 23,480,998 shares held by its largest shareholder, Tianjin Ruimei Scientific Instrument Co., Ltd.[77]. - The company has a lock-up period of 36 months for shares held by its controlling shareholders, preventing any transfer or management delegation during this time[51]. - The company has a total of 22 subsidiaries, with 17 being wholly-owned and 5 being equity investments, enhancing operational efficiency and cost reduction[43]. Accounting Policies and Financial Reporting - The company adopted new accounting standards effective from May 28, 2017, which resulted in changes to accounting policies but did not affect the net profit for the reporting period[71]. - The financial report indicates that there are no changes in the controlling shareholder or actual controller[83]. - The company has not reported any significant accounting errors that require retrospective restatement during the reporting period[72]. - The company's accounting policies comply with the requirements of the enterprise accounting standards, ensuring a true and complete representation of financial information[130].

公司代码：603716 公司简称：塞力斯 武汉塞力斯医疗科技股份有限公司 2017 年第一季度报告 1 / 17 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 5 | | 四、 | 附录 | 7 | 2017 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 2017 年第一季度报告 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | | | | | 减(%) | | | 总资产 | 1,097,197,495.58 | 1,092,480,920.37 | | 0.43 | | 归属于上市公司 | 852,754,658.19 | 843,613,981.87 | | 1.08 | | 股东的净资产 | | | | | | | 年初至报告期末 | ...

Financial Performance - The company's operating revenue for 2016 was CNY 627,328,056.89, an increase of 18.44% compared to CNY 529,659,702.51 in 2015[21]. - The net profit attributable to shareholders for 2016 was CNY 68,917,864.86, reflecting a growth of 12.14% from CNY 61,459,327.05 in 2015[21]. - The net profit after deducting non-recurring gains and losses was CNY 67,335,059.58, up 12.90% from CNY 59,640,790.78 in 2015[21]. - The company's total assets increased by 64.71% to CNY 1,092,480,920.37 at the end of 2016, compared to CNY 663,266,667.65 at the end of 2015[21]. - The basic earnings per share for 2016 was CNY 1.71, a 6.21% increase from CNY 1.61 in 2015[22]. - The weighted average return on equity for 2016 was 12.59%, down from 14.29% in 2015[23]. - The company reported a negative cash flow from operating activities of CNY -17,016,112.18 in 2016, a decrease of 136.91% compared to CNY 46,106,511.33 in 2015[21]. - The gross profit margin for the concentrated sales business was 34%, with a revenue increase of 24% year-on-year[59]. - The company achieved a revenue of 627,328,056.89 CNY, representing an 18% year-on-year growth[55]. - The net profit attributable to shareholders was 68,917,900 CNY, reflecting a 12.14% increase compared to the previous year[55]. Dividend Policy - The company proposed a cash dividend of RMB 0.80 per 10 shares, totaling RMB 4,075,200, which accounts for 10% of the distributable profit for the year 2016[2]. - The company has a cash dividend policy that aims for a minimum of 30% of the average distributable profit over the last three years to be distributed in cash[93]. - The company will prioritize cash dividends, aiming for at least 80% of profits to be distributed in cash during mature phases without major capital expenditures[95]. - The company proposed a three-year shareholder dividend return plan for 2017-2019 during the board meeting on January 21, 2017[98]. - In 2016, the company did not distribute any dividends, with a cash distribution amount of 4,075,200 RMB, representing 10% of the distributable profit[100]. - The company has not proposed a cash profit distribution plan despite having positive profits available for ordinary shareholders[101]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and development strategies[3]. - The company has detailed various risks and countermeasures in its operational analysis section[5]. - The company aims to mitigate operational risks related to increased industry competition and reliance on suppliers[87]. - The company faces risks from intensified industry competition, with many players in the domestic IVD market, and plans to accelerate industrial and regional layout to enhance core competitiveness[90]. - Accounts receivable increased due to rapid business growth, with a significant portion of clients being medical institutions with long payment terms of 3-6 months, potentially impacting cash flow[90]. Corporate Governance - The company received a standard unqualified audit report from Zhongshun Zhonghuan Accounting Firm[4]. - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management[4]. - The company held three shareholder meetings and seven board meetings during the reporting period to enhance corporate governance[52]. - The company has implemented a series of internal governance structures to enhance operational transparency and protect shareholder interests[153]. - The board of directors held 7 meetings during the year, with a mix of in-person and communication methods, ensuring active participation in governance[157]. Market Position and Strategy - The company operates in the medical technology sector, focusing on in vitro diagnostic products[10]. - The company has established long-term contracts with medical institutions for integrated sales of diagnostic instruments and reagents[10]. - The company focuses on integrated marketing and service business for in vitro diagnostic products, enhancing its competitive edge through strategic partnerships with suppliers[31]. - The company has established a leading position in the IVD sector through its centralized sales model, which enhances procurement efficiency for medical institutions[35]. - The domestic IVD industry has maintained a compound annual growth rate of over 15% in recent years, indicating a strong market potential[50]. Research and Development - Research and development expenses amounted to 7,889,555.07 CNY, a decrease of 5% from the previous year[58]. - The company has 34 R&D personnel, making up 10.93% of the total workforce[68]. - The company has 93 ongoing research projects, with 81 projects having completed laboratory development by the end of the reporting period[78]. - The company is focusing on enhancing its product offerings in coagulation, biochemical, immunological, and colloidal gold diagnostic reagents[87]. Financial Structure - The company has a total share capital of 50,940,000 shares as of December 31, 2016[2]. - The company's total liabilities at the end of the reporting period were RMB 192,967,679.31, indicating a reduction in financial leverage[124]. - The total number of ordinary shares increased from 38,200,000 to 50,940,000, reflecting a 33.33% increase in share capital[124]. - The company's cash and cash equivalents increased by 265.79% to 353,784,266.90, primarily due to funds raised from stock issuance[72]. - The company reported a total capital increase of 12,740,000.00 from shareholder contributions during the current period[193]. Human Resources - The total number of employees in the parent company and major subsidiaries is 445, with 293 in the parent company and 152 in subsidiaries[149]. - The professional composition includes 184 technical personnel, 75 sales personnel, and 22 R&D personnel, indicating a strong focus on technical and sales capabilities[149]. - The educational background of employees shows that 18 hold master's degrees or above, while 148 have bachelor's degrees, highlighting a well-educated workforce[149]. - The total remuneration paid to directors, supervisors, and senior management during the reporting period amounted to 5.685 million yuan[147]. Compliance and Legal Matters - There are no major lawsuits or arbitration matters reported for the year[111]. - The company has no significant related party transactions or major contracts that require disclosure[114]. - The company has not faced any penalties from securities regulatory agencies in the past three years[148]. - There are no changes in the controlling shareholder or actual controller during the reporting period[134].